Lancôme, the L’Oréal-owned luxury brand, is aiming to further secure its position as a leader in the longevity beauty game through the launch of a new skin care range.
The yet-to-be-named collection is centred on Swiss biotech firm Timeline’s Mitopure technology, a proprietary molecule backed by more than US$50m in R&D and 15 years of research.
The ingredient is a highly pure form of Urolithin A, a postbiotic that is said to be clinically proven to re-energise mitochondria – the powerhouses of the cell – through a cellular renewal process known as mitophagy – the removal of damaged mitochondria.
It marks L’Oréal Groupe’s first consumer launch with Timeline, following the French beauty giant's investment in the firm in 2024 through a CHF56 million Series D funding round.
The range will be revealed and launched at the annual American Academy of Dermatology (AAD) convention in Denver, Colorado, from 27 - 29 March 2026.
Mitropure has been most commonly used in Timeline’s longevity supplements, but the new skin care line will combine the molecule with Lancôme’s proprietary compounds to deliver longevity benefits via the skin itself.
Unpacking Mitopure and its longevity benefits
Each product in the range has been designed to address the skin's visible biological age – the measure of the actual physiological condition and maturity of skin cells – and is Mitopure’s first deployment at a global scale through a major beauty brand.
And it is this scale, and how it “translates longevity science into sensorial luxury formulas designed for everyday use”, that will help the range stand out in the longevity arena, Vania Lacascade, Global Brand President of Lancôme, told Cosmetics Business.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cosmetics Business.
Subscribe now Already a subscriber? Sign in here.